Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 18INDUSTRY 4NIH 2FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Thoracic 1

Conditions

Colorectal Neoplasms 108Stomach Neoplasms 68Pancreatic Neoplasms 32Neoplasms 24Lymphoma, Large B-Cell, Diffuse 22Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 18Rectal Neoplasms 17Colonic Neoplasms 17Esophageal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 13Adenocarcinoma 13Carcinoma, Hepatocellular 12Ovarian Neoplasms 10Biliary Tract Neoplasms 9Adenocarcinoma Of Esophagus 9Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Gastrointestinal Neoplasms 7Lymphoma, Non-Hodgkin 6Endometrial Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Carcinoma, Pancreatic Ductal 4Breast Neoplasms 4Advanced Solid Tumor 4Solid Tumors 3

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Oxaliplatin × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00356122 2011-10-17

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Sanofi

Phase 2 Completed
53 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡